

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated May 5, 2020 (the “Prospectus”) of Peijia Medical Limited (the “Company”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to sell, acquire, purchase or subscribe for any securities. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.*



**Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

**FULL EXERCISE OF THE OVER-ALLOTMENT OPTION,  
STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

## **FULL EXERCISE OF THE OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option described in the Prospectus has been fully exercised by the Joint Global Coordinators on behalf of the International Underwriters on June 7, 2020, in respect of an aggregate of 22,876,000 Shares (the “**Over-allotment Shares**”), representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return of the borrowed Shares under the Stock Borrowing Agreement which were used to cover over-allocations in the International Offering.

## **STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

The Company further announces that the stabilization period in connection with the Global Offering ended on June 7, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Further information on the stabilizing actions undertaken by the Stabilization Manager during the stabilization period is set out in this announcement.

## **FULL EXERCISE OF THE OVER-ALLOTMENT OPTION**

The Company announces that on June 7, 2020 the Over-allotment Option described in the Prospectus has been fully exercised by the Joint Global Coordinators, on behalf of the International Underwriters, in respect of an aggregate of 22,876,000 Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), to cover over-allocations in the International Offering.

The Over-allotment Shares will be allotted and issued by the Company at HK\$15.36 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering. The Over-allotment Shares will be used to facilitate the return of 22,876,000 borrowed Shares to XinYue International Limited, which were used to cover over-allocations of Shares in the International Offering.

## **APPROVAL OF LISTING**

Approval for the listing of, and permission to deal in, the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of, and dealing in, the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on June 10, 2020.

## SHAREHOLDING STRUCTURE OF THE COMPANY UPON THE FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after the completion of the full exercise of the Over-allotment Option is as follows:

Shareholders	Immediately before the allotment and issue of the Over-allotment Shares		Immediately after the allotment and issue of the Over-allotment Shares	
	<i>Number of Shares</i>	<i>Approximate percentage of the Company's issued share capital</i>	<i>Number of Shares</i>	<i>Approximate percentage of the Company's issued share capital</i>
The Concert Parties <sup>(1)</sup>	144,436,380	23.68%	144,436,380	22.82%
LAV Aero Limited	42,428,460	6.96%	42,428,460	6.70%
Shanghai Liyi Biotech, L.P. 上海禮軼生物科技合夥企業 (有限合夥)	19,952,740	3.27%	19,952,740	3.15%
Matrix Partners China IV, L.P. <sup>(2)</sup>	36,050,780	5.91%	36,050,780	5.70%
Matrix Partners China IV-A, L.P. <sup>(2)</sup>	3,604,660	0.59%	3,604,660	0.57%
HH SUM-XXIV Holdings Limited	42,698,980	7.00%	42,698,980	6.75%
MGR International Limited <sup>(3)</sup>	19,641,380	3.22%	19,641,380	3.10%
Flexmed International (HK) Limited <sup>(3)</sup>	16,400,000	2.69%	16,400,000	2.59%
Other pre-IPO Shareholders <sup>(4)</sup>	129,190,620	21.18%	129,190,620	20.41%
Other public Shareholders	155,638,000	25.51%	178,514,000	28.20%
<b>Total</b>	<b>610,042,000</b>	<b>100.00%</b>	<b>632,918,000</b>	<b>100.00%</b>

*Notes:*

- (1) Dr. Zhang, Jinnius Drive Trust, Mrs. Zhang, Hanlindale Trust, Ms. Hong Ye and XinYue International Limited are Concert Parties based on the Concert Party Agreement. Therefore, each of Dr. Zhang, Jinnius Drive Trust, Mrs. Zhang, Hanlindale Trust, Ms. Ye and XinYue International Limited is deemed to be interested in the aggregate equity interests of all the Concert Parties. For details, please refer to the section headed “History, Development and Corporate Structure – Our Founders and Concert Party Arrangement” in the Prospectus.

Jinnius Drive Trust and Hanlindale Trust were respectively established by Dr. Zhang and Mrs. Ping Ye Zhang as grantor. Both Dr. Zhang and Mrs. Zhang are trustees of Jinnius Drive Trust and Hanlindale Trust. Therefore, each of Dr. Zhang and Mrs. Zhang is deemed to be interested in an aggregate 1,640,378 Shares held by the two trusts, including 785,678 Shares held by Jinnius Drive Trust and 854,700 Shares held by Hanlindale Trust.

XinYue International Limited was owned as to 65% by Dr. Zhang and 35% by Ms. Hong Ye. Therefore, under the SFO, each of Dr. Zhang and Ms. Hong Ye is deemed to be interested in 4,534,282 Shares held by XinYue International Limited.

Dr. Zhang and Mrs. Zhang are spouses, and are therefore deemed to be interested in the equity interests held by each other.

- (2) To the best of our Directors’ knowledge, Matrix China Management IV, L.P. is the general partner of Matrix Partners China IV, L.P. and Matrix Partners China IV-A, L.P., both are our beneficial owners. The general partner of Matrix China Management IV, L.P. is Matrix China IV GP GP, Ltd.. Therefore, under the SFO, each of Matrix China Management IV, L.P. and Matrix China IV GP GP, Ltd. is deemed to be interested in an aggregate 1,982,772 Shares held by Matrix Partners China IV, L.P. and Matrix Partners China IV-A, L.P.
- (3) To the best of our Directors’ knowledge, both MGR International Limited and Flexmed International (HK) Limited are wholly-owned by Ms. Jin Zhu. Therefore, under the SFO, Ms. Jin Zhu is deemed to be interested in an aggregate 1,802,069 Shares held by MGR International Limited and Flexmed International (HK) Limited.
- (4) These refer to all other Pre-IPO Investors and early investors. For details, please see the section headed “History, Development and Corporate Structure” in the Prospectus.

## **USE OF PROCEEDS**

The Company will receive additional net proceeds of approximately HK\$335.5 million from the issue of the Over-allotment Shares, after deducting the commission and other offering expenses payable by the Company in relation to the exercise of the Over-allotment Option (without taking into account any discretionary incentive fees). The Company intends to utilize the additional net proceeds on a pro rata basis for the purposes as set out in the section headed “Future Plans and Use of Proceeds – Use of Proceeds” in the Prospectus.

## STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on June 7, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by Morgan Stanley Asia Limited, as Stabilization Manager, or any person acting for it during the stabilization period were:

- (1) over-allocations of an aggregate of 22,876,000 Shares in the International Offering, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (2) the borrowing of 22,876,000 Shares by Morgan Stanley & Co. International plc, as an affiliate of the Stabilization Manager, from XinYue International Limited, pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering. Such Shares will be returned and redelivered to XinYue International Limited in accordance with the terms of the Stock Borrowing Agreement; and
- (3) the full exercise of the Over-allotment Option by the Joint Global Coordinators, on behalf of the International Underwriters on June 7, 2020, in respect of an aggregate of 22,876,000 Shares, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), at the Offer Price, to facilitate the return to XinYue International Limited of all of the borrowed Shares which were used to cover the over-allocations in the International Offering.

There had been no purchase or sale of any Shares on the market for the purpose of price stabilization by the Stabilization Manager during the stabilization period.

## PUBLIC FLOAT

Immediately after the completion of the Global Offering and after the full exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) and Rule 18A.07 of the Listing Rules.

By order of the Board  
**Peijia Medical Limited**  
沛嘉醫療有限公司  
**Dr. Yi Zhang**  
*Chairman and executive Director*

Hong Kong, June 7, 2020

*As of the date of this announcement, the executive Directors are Dr. Yi Zhang, Ms. Ping Ye Zhang and Ms. Hong Ye, the non-executive Directors are Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Bing Shang and the independent non-executive Directors are Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wayne Wu and Mr. Wai Ming Yip.*